StockWatch
·
BIJOY HANS LTD. · QQ2 FY-2027 · THE CALL

Expansion on track, occupancy ramp a near-term headwind

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsARVAYABIJOY HANS LTD.20 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

First full consolidated year; acquisition dilution explained transparently, occupancy compression expected but needs 50%+ ramp.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Strong bed expansion roadmap (2,400 by FY30) and stable EBITDA margins (13-14%) underpin long-term upside, but Q2 occupancy fell to 38% from 48% YoY despite bed additions, signaling near-term ramp-up risk. PAT margins thin at 3.4%, vulnerable to cost inflation.

₹40.3 Cr

Revenue · +null% YoY

₹1.4 Cr

Reported PAT · +541.6% YoY

Flat

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Q2 revenue INR40 crores

MET

Delivered Q2 revenue ₹40.3 Cr

PAT INR1.37 crores in Q2

MET

Delivered PAT ₹1.4 Cr (minor rounding difference)

EBITDA margin 13% in Q2

MET

Delivered OPM 13.0%, consistent with stated 13% EBITDA margin

Occupancy declined to 38% from 48% YoY

MET

Occupancy compression documented; new units at 27%, mature at 46-56%

ARPOB rose 17% YoY

MET

Transcript states average revenue per bed improved 17% YoY; revenue growth 35% QoQ with 262→517 bed base suggests revenue/bed growth

Earnings quality

What changed since the last call

Deltas vs. the prior call

Occupancy guidance implicit

Downgrade

No prior formal guidance; Q2 showed 38% occupancy vs 48% a year ago due to new unit drag

Suhodha acquisition closed Nov 1

New

₹1 Cr monthly revenue run-rate, ₹70-80 lakh profit; pure bolt-on to SeCURE GI network

Tech spend earmarked

New

₹4.5 Cr for rights issue tech (SecurANT, GIT), ₹2-3 Cr annual cost going forward; MyArvaya monetization deferred

The Q&A

Q&A was probing and candid. Analysts pressed on occupancy decline, margin sustainability, and government scheme exposure; management deflected none, explained each squarely (new units mature slower, government schemes ~15-20% of business, EBITDA 13-14% sustainable). One soft answer: diagnostic network plans left vague ('in pipeline, can't disclose'). Overall: direct, no evasion.

The exchanges that mattered

Occupancy ramp — Vikrant Sahu, RK Advisors

Answered

New acquisitions (262→517 beds) have 27% occupancy; mature units 46-56%. Discharges up >20% YoY, occupancy growing QoQ. Ramp as units fit-out and new MoUs operationalize.

ARPOB drivers — Vikrant Sahu, RK Advisors

Answered

Specialty mix shift to super-specialty (cardio, neuro, kidney, robotic surgery) and surgery work; pricing minimal in inflation. All hospitals super-specialty majority.

Government scheme exposure — Vikrant Sahu, RK Advisors

Answered

Government business ~15-20%, oscillates 15-20%. Profitability higher at payer/private; government business helps occupancy utilization and overall EBITDA.

Borrowing & capex — Jimit Mehta, Mehta Investments

Answered

Borrowings for capex and medical equipment fit-outs as beds ramp. Operating cash flow up 89% of EBITDA in H1; no liquidity stress. Rights issue (₹206 Cr) funds new medical equipment and acquisitions.

New hospital margins — Jimit Mehta, Mehta Investments

Partial

Regular hospitals mature; new increasing in occupancy. EBITDA margins sustainable 13-14% long-term. Some time till acquisition hits 50%+ occupancy, then EBITDA margin improves.

Sigipl acquisition update — Jimit Mehta, Mehta Investments

Answered

Specialized GI hospital (pancreatic, liver surgeries), ₹1 Cr monthly turnover, 100% share swap, no cash outlay. Grows gastrointestinal specialty and builds on SeCURE GI network.

Cybersecurity & data privacy — Shravan Modi, Syndicate Family Office

Answered

Architecture ground-up HIPAA/HL7/FHIR/DPDP compliant. Clinical intelligence engine agnostic to HIS, sits outside; consent built-in. All tech stack compliant; consent wired into everything.

Goa resort repurposing — Shravan Modi, Syndicate Family Office

Partial

Being repurposed for wellness. Currently low occupancy (repurposing in progress); numbers will be available next quarter.

Diagnostic network expansion — Viraj Shah, Vairag Capital

Dodged

Diagnostics very key; building lab and home collection services. Feeders (sub-labs nearby) planned; integrated lab model going forward. Details 'in pipeline,' can't discuss yet.

MyArvaya monetization — Jignesh, North Star Investments

Partial

35,000+ OPD patients/month; app live in SeCURE network. Monetization not yet; engagement first. By next quarter, all SeCURE patients in app. Longer-term external digital health/continuity use.

Tech spend & ROI — Jignesh, North Star Investments

Answered

₹4.5 Cr capitalized on rights issue (SecurANT, GIT license). Annual cost ₹2-3 Cr max as usage/volume scale. High capex now, but normalized as growth happens.

Guidance

Forward guidance and management's confidence

No explicit FY27/FY28 revenue target stated

Medium

Bed expansion roadmap (791 by Dec, 2,400 by FY30) is qualitative; no revenue CAGR or FY27 absolute number given

EBITDA margin 13-14% sustainable going forward

High

Q2 at 13%, H1 at 13.1%. Management expects range 13-14% even as acquisitions ramp to 50%+ occupancy

₹2-3 Cr annual tech spend; ₹23.6 Cr per 100-bed hospital

Medium

Rights issue ₹206 Cr earmarked for tech, medical equipment, acquisitions. Lease model dominant (asset-light)

Risks the call surfaced

Ranked by how much they should concern a holder

Occupancy ramp-up

High

New units (262→517 beds in 6m) running at 27% vs mature units 46-56%; occupancy compression to 38% vs 48% YoY

PAT margin erosion

Medium

PAT margin 3.4% is very thin; hospital wage/energy costs rising; leverage at 0.45x equity means less buffer

Tech monetization uncertainty

Medium

MyArvaya app spend ₹4.5 Cr capitalized; ₹2-3 Cr annual cost going forward; monetization deferred to 'later' (beyond engagement phase)

Geographic concentration

Low

Hubballi unit at 56.5% occupancy; Karnataka/Maharashtra dominate. Interstate expansion (Jalna, Sangli, Shivamogga) pending execution

Acquisition integration

Low

255 beds added in 6m; Sigipl (Suhodha GI) added Nov 1 at ₹1 Cr monthly revenue; fit-out and ramp-up timelines uncertain

Management

Score 7/10. Clear on strategy (HMO, tech, bed roadmap). Transparent on occupancy headwinds (new units at 27%). Deferred diagnostic expansion details ('in pipeline, can't discuss yet') but no evasion on core metrics. First full consolidated year; H1 on track (₹70.19 Cr revenue, 13.1% EBITDA margin). Acquisitions diluting occupancy (38% vs 48%) but as expected. ARPOB +17% shows quality upside offsetting volume dilution.

What to watch next
  • 1 · Dec 2026

    791 beds target; Sushodha GI ramp

  • 2 · Q3 FY27

    MyArvaya app launch with patient engagement features

  • 3 · FY27 end

    MoU 220 beds (Jalna, Sangli, Shivamogga) execution begins

PAT margins thin at 3.4%, vulnerable to cost inflation.

Informational and educational content only. Not investment advice.